Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line tislelizumab monotherapy in platinum-ineligible advanced or metastatic urothelial carcinoma
ChiCTR2400085687Phase 2Not yet recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in transitional cell carcinoma (TCC), sponsored by Army Medical Center of PLA. Primary endpoint: Objective response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2400085687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085687.